Need professional-grade analysis? Visit stockanalysis.com
$11.95B
15.06
2,435
4.24%
Henan Lingrui Pharmaceutical Co Ltd (600285) trades on SHG in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY21.08, down 0.75% from the previous close.
Over the past year, 600285 has traded between a low of CNY20.52 and a high of CNY24.46. The stock has lost 3.6% over this period. It is currently 13.8% below its 52-week high.
Henan Lingrui Pharmaceutical Co Ltd has a market capitalization of $11.95B, with a price-to-earnings ratio of 15.06 and a dividend yield of 4.24%.
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules; and Tongluo pain relief creams, Huoxuexiaotong tinctures, bone strengthening musk pain relief creams, indomethacin patches, abdominal soothing plasters, children's paracetamol and phenylephrine granules, children's kechuanling granules, montmorillonite powders, medical cooling patches, three yellow pearl creams, mometasone furoate creams, mupirocin ointments, bluestone particles, ke ning capsules, xiao chaihu tablets, and ruishuan fentanyl transdermal patches. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.
Side-by-side comparison against top Healthcare peers.